Amplia Therapeutics (Amplia Therapeutics) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Amplia Therapeutics's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.00.

Amplia Therapeutics's long-term debt to total assets ratio declined from Sep. 2022 (0.01) to Sep. 2023 (0.00). It may suggest that Amplia Therapeutics is progressively becoming less dependent on debt to grow their business.

Amplia Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Amplia Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics LT-Debt-to-Total-Asset Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.01

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.09	0.01	0.01	-

Amplia Therapeutics LT-Debt-to-Total-Asset Calculation

Amplia Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )	/	Total Assets (A: Mar. 2023 )
	=	0.063	/	12.473
	=

Amplia Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )	/	Total Assets (Q: Sep. 2023 )
	=	0.035	/	11.285
	=

Amplia Therapeutics (OTCPK:INNMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Amplia Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024